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Ageing of the population is accompanied by an important
health shift. On the one hand, there is a decreased prevalence of
senior adults presenting with one single disease, so-called
“primary” or “index” disease, and on the other hand, there is an
increased prevalence of co-occurring diseases in the same
individual (1). 
To better address these issues and their consequences, the
NIA taskforce co-existing health conditions recently proposed
new definitions (2). The term “co-morbidity” corresponds to
one primary or index disease associated with specific 2or
multiple concurrent conditions, while the term “multi-
morbidity” corresponds to the sum of conditions without a
specific primary or index disease (2).  Applied to cancer
patients, these definitions stress the management challenge of
oncologists dealing with aged patients whose complexity is no
more captured by lists of diagnoses or biological burden alone
(3, 4, 5). The co-existing health conditions of many senior
cancer patients require tailoring the screening procedure, to
adapt the treatment options and to modify the prognosis
evaluation (3, 4, 5).   
The most publicized scoring system for senior cancer
patients is the comprehensive geriatric assessment (CGA) (6). It
consists of a multidimensional data-search and analytic process
of patient characteristics aiming to an individualized
intervention-plan. CGA was proven to allow comprehensive
identification of the patients’ health problems and to facilitate
the choice of the most adequate treatments (7, 8). However,
neither is the survival quantity enhanced nor is its quality
improved by CGA (8). A combination of CGA and of
supportive measure during follow-up management is therefore
an attractive option (7).
In this context, the emergence of the concept of frailty is
likely to further complicate the already existing complexity of
senior of cancer patients, whose clinical features are quite
similar. Frail subjects are anorexic, weak, exhausted, and
inactive with impaired homeostatic reserves and reduced
capacity to withstand any kind of stress (9). The health
consequences of frailty modify cancer management with a
negative impact on prognosis. Recurrent falls, trauma,
polypharmacy, repeated hospital admissions may lead to cross-
infections, disability and death (10). 
The challenge of not missing frailty features in senior cancer
patients explains the request to better identify this subtle
condition in cancer trials.
Randomized controlled trials focused on frail elders with
cancer
The website www.clinicaltrials.gov gathers and updates all
randomized controlled studies performed throughout the world
(11). Forty are dedicated to frail elders with only 8 devoted to
frail cancer elders. Among these, six are disease or treatment
specific, one includes all kind of cancers and one is an ongoing
opinion analysis. Main issue of these studies is to determine
how frail senior cancer patients are assessed. 
Randomized controlled studies of frail elders with cancer 
Inclusion criteria in these studies illustrate the diversity of
opinions about the frailty syndrome: i) age 60 to 70 without co-
morbid illness ii) patients with decreased cardiac ejection
fraction or pulmonary dysfunction or elevated liver tests or
hepatitis C infection or poor performance status iii) 65+ female,
post menopausal status and one of the following characteristics
of frailty: over 85 years of age, history of 3 falls in the past 6
months, more than 3 co-morbidities, mild dementia (must be
oriented in time, space and location) and at least one ADL
inability (11) . The criteria used to define “frail old cancer
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patients” have thus not reached the stage of a consensual
operational definition.  
In a study about 99 frail cancer patients who receive in-
and/or out-patients specialized geriatric care after stabilisation
of their diseases, at least 2 of the following conditions defined
frailty: previous stroke, falls, hospital admission 3 months
before inclusion, 1 or 2 ADL inabilities, difficulty ambulating,
prolonged bed rest, malnutrition, incontinence, dementia and
depression. Such criteria are very broad and may include other
geriatric patients than the frail. With no surprise, the results of
the study demonstrated better pain control and better mental
health scores after 1 year in in-patients receiving specialized
geriatric care (12) .
Randomized controlled surveys on opinion analysis
The unique on-going survey on this topic concerns views
and attitudes of oncologists (N = 150) and general practitioners,
internists and geriatricians (N = 150) on the use of
chemotherapy/hormone therapy in older and/or frail women
with breast cancer. Inclusion criteria for doctors include more
than 2 years in practice, more than 25 post menopausal breast
cancer patients on adjuvant hormonal therapy under care and
not being linked to any advertising, market research or drug
company. The main goals of the survey are i) to evaluate the
impact on care management and treatment recommendations of
age, health and daily functioning of patients and ii) to
determine if any consensual attitudes exist between medical
doctors with different training (11) . The results of this survey
will be of importance to define better inclusion criteria of frail
senior cancer patients and to avoid age discrimination.
Despite many ongoing difficulties in the definition of frailty,
it is encouraging to see oncologists taking into account the
physiological age of patients which is the reflection of a normal
but sometimes abnormal accelerated loss of body reserves (13).
It is though true that CGA is time consuming and that too few
geriatricians are available to help in caring for old and frail
cancer patients.
Searching new assessment tools in frail cancer patients
A recent review of all geriatric assessment tools for cancer
patients underlines once again the value of CGA. Its limited use
in daily clinical practice is highlighted with the need to identify
more convenient functional scales (6). A comparison between
CGA and different types of frailty assessment scales is thus
needed.
Very few tools were already tested in cancer patients
The Cumulative Illness Rating Scale - Geriatric (CIRS-g)
was used in breast (14), lung (15) and rectal (16) cancer
patients to determine the impact of co-morbidity on the overall
survival. In each of the above mentioned study, co-morbidity
score increases with age. However, age, co-morbidity and
weight loss (17) or disease severity (18) are also independent
prognostic factors of overall survival 
The Karnosky Performance Status (KPS) is of interest in
young patients but it has not been validated in senior adult
cancer patients (6). A retrospective analysis of survival factors
in 30 patients aged 70 and older with grade 3 and 4 malignant
gliomas showed that KPS is the only significant prognostic
factor in multivariate analysis (19). Prospective studies of KPS
in old cancer patients are thus needed.  
The Vulnerable Elders Scale (VES-13)
It is a 5-minutes self-administrated scale including 4
categories of items corresponding to age, self rated health,
physical disabilities (N = 6) and functional disabilities (N = 5)
(20). Neither co-morbidity data nor mental/cognitive evaluation
is part of the evaluation.  
VES-13 was compared to CGA in a pilot study of 50
prostate cancer patients (70 to 82 years) treated with androgen
ablation. The Pearson correlation coefficient testified the
reliability of VES-13 at 0.92. However, when excluding the age
criteria, reliability of VES-13 went down to 0.52 for self-rated
health, 0.60 for self rated physical ability and 0.70 for self rated
functional ability (21).
The Mini Nutrional Assessment (MNA) short form was part
of a CGA including also MMSE, get up and go test, bADL,
iADL, GDS and CIRS-G to evaluate 364 cancer patients
(median age: 77.5 y., sex ratio H/F 1.43) accrued in 12 French
centres. They were suffering of different cancers: 110
lymphomas, 101 colon, 37 stomach, 37 lung, 23 pancreas, 20
prostate, 18 bladder, 14 ovary cancers and 4 from unknown
location and type. Sixty six percent of the cancer patients had
advanced tumours. The early death predicted by logistic
regression was linked to the MNA short form (O.R. = 4.5 [1.75
-11.6]) and the advanced disease (O.R. = 4.2 [1.70 -10.3]) (22).
These encouraging results must be confirmed by prospective
studies keeping in mind that short survival is not a frailty
feature but the most dramatic consequence of the frailty
syndrome.
The Abbreviated CGA (aCGA) corresponds to a simplified
form of CGA including 15 selected items from the main
geriatric scales: 6 from the MMSE, 4 from the GDS, 3 from the
bADL and 4 from the iADL. The global score determines the
benefit for the patient to get an entire CGA (eCGA). The aCGA
was retrospectively used for the evaluation of 500 charts of old
cancer patients. The aCGA / eCGA correlations ranged from
0.84 to 0.96, testifying that aCGA can be helpful in screening
for patients who would benefit from an eCGA (23). As
previously mentioned, it is not yet known whether aCGA has
an impact on treatment decision, choice and tolerance as well as
on survival.
Other potential screening tools not yet tested in frailty
cancer patients
Numerous other tools have been used to assess the frailty
status of non-cancer old persons. It seems useful to mention
some of them focusing on gait ability.
The one leg standing balance test
This test applied in a cross-sectional study in an urban
community dwelling population (N = 512, m.a. = 73 y ± 7.0,
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71.4% women) showed that 24.7% had abnormal one leg
standing balance. In 60.6%, abnormalities are linked to an
iADL deficit. In addition, abnormal one leg standing balance is
significantly linked to age over 71 years (O.R. = 5.11 [CI =
1.99 – 13.10]), iADL deficit (transports) (O.R. = 3.61 [CI =
1.15 – 11.40]) and poor health status (O.R. = 2.67 [CI = 1.35 –
5.27]) 24.
The gait speed
Four hundred twenty four volunteers aged 70-89 years were
randomly assigned to two interventions: physical activity or
educational programme for a planned minimum of 12 months.
They were assessed by 4 different techniques: short physical
performance battery, self-reported disability scale, 4 meters
walks (less than 10 seconds) and 400 meters walk (less than 15
minutes). The ability to walk 400 meters as a dichotomous
outcome appears as the most interesting measure to appreciate
the results of the intervention programme (25). 
The gait velocity
Gait velocity was tested in 102 well functioning participants
(m.a. = 79.6 ± 4 years) and then followed-up during 24 months.
Low gait velocity (<0.7 m/s) measured on a 8 to 10 meters walk
appeared to be a good predictor of requirement of a care giver
(RR: 9.5 [1.3 - 2.5]), hospitalization (RR: 5.9 [1.9 - 8.5]) and
new falls (RR: 5.4 [12.0 – 4.3]) (26). 
The gait variability
The gait variability of 379 older adults (m.a = 79 y.)
community dwelling, free of mobility disability by self report
was tested using a GaitMat II (4-meter-long walkway). Then,
mobility disability was self reported by telephone contact every
6 months during 54 months. The incident mobility disability
reached 58.6% during the study period. Cox proportional
hazard models after adjusting for gait speed, demographics,
chronic conditions, prescription of medications, health status
and level of physical activities showed that the initial increased
in stance time variability of 0.001 second. Is linked with a 13%
higher incidence of mobility disability (27). 
Conclusion
The need of senior cancer patients to benefit of a
comprehensive geriatric assessment including follow-up
management was well demonstrated. It allows i) a better
identification of the health problems of the cancer patient,
including frailty–risk, ii) an easier choice of appropriate and
better tolerated treatment iii) a longer survival. However the
main difficulties of oncologists are linked to the availability of
geriatricians performing such a long assessment. The need to
find and validate short pre-treatment assessment tools for senior
cancer patients appears urgent. The analysis of past and on-
going randomized controlled trials in frail patients with cancer
emphasized on further and larger research. 
Pre-treatment geriatric assessment i) has to be validated in
patients whatever their age ii) and whatever the cancer type iii)
will facilitate the choice of cancer treatments iv) will have to be
followed by geriatric management and v) will allow longer and
hopefully better survival. Geriatricians are now confronted to
outstanding research challenges. Results of large randomized
controlled trials will soon be able to predict frailty thanks to
systematic evaluation with simple, easy and reliable tools.
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